Skip to main content

Table 2 Outcomes of patients with CRE infections who received ceftazidime-avibactam compared with comparative group (received different CRE specific antibiotics)

From: Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae

Outcome

Ceftazidime/Avibactam group n = 10 (%)

Comparative group n = 28 (%)

P value

Clinical remission

8 (80)

15 (53.6)

0.14

Clinical cure without relapse or

4 (40)

11 (39)

> 0.99

death within 30 days

 30 days all-cause mortality

5 (50)

16 (57.1)

0.7

 Attributable mortality to CRE

2 (20)

11 (39.3)

0.27

 Length of stay, median (IQR), days

69.5 (47.5–96)

40.5 (22–79.5)

0.07

 30-days relapse of the same isolate

2 (20)

1 (3.6)

0.1

 Time to clearance of bacteremia,

4 (3–5)

5 (3–7)

0.65

median (IQR), days

  1. CRE Carbapenem-resistant Enterobacteriaceae, IQR Interquartile range